Clinique De La Sauvegarde

The department advances patient comfort and surgical safety by evaluating innovative pain‑relief methods and imaging tools. Studies include the use of erector spinae plane block for acute low back pain and the application of indocyanine green fluorescence angiography to assess anastomotic perfusion during colorectal surgery.

• Intraoperative fluorescence imaging to reduce anastomotic leakage
• Regional nerve block techniques for postoperative analgesia
• Real‑time monitoring of tissue perfusion in abdominal procedures
• Evaluation of non‑opioid pain management strategies

Clinique De La Sauvegarde integrates these techniques to enhance recovery and minimize complications for patients undergoing complex surgeries.

Research at the site targets malignancies of the gastrointestinal tract, aiming to improve survival and preserve organ function. Trials explore total neoadjuvant therapy for rectal adenocarcinoma, the benefit of intensified adjuvant chemotherapy such as modified FOLFIRINOX for ampullary cancer, and targeted agents like tinengotinib in FGFR‑altered cholangiocarcinoma.

• Neoadjuvant strategies for intermediate‑risk rectal cancer
• Adjuvant chemotherapy comparisons after digestive tumor resection
• Targeted therapy for FGFR‑mutated cholangiocarcinoma
• ctDNA‑guided treatment decisions in colon cancer
• Comparative effectiveness of FOLFOX versus gemcitabine in pancreatic adenocarcinoma

These investigations at Clinique De La Sauvegarde seek to lower recurrence rates and extend disease‑free intervals for patients with digestive system cancers.

The hematology department contributes to the management of advanced prostate cancer by testing combination and repurposed therapies. One study evaluates the impact of acetylsalicylic acid and atorvastatin on overall survival in castration‑resistant disease, while another examines hormone‑therapy sequencing guided by circulating tumor DNA mutations.

• Cardiovascular agents as adjuncts in castration‑resistant prostate cancer
• ctDNA‑directed early switch from aromatase inhibitor to fulvestrant
• CDK4/6 inhibitor combined with endocrine therapy and safety monitoring
• Strategies to mitigate hematologic toxicities in prostate cancer treatment

Clinique De La Sauvegarde’s efforts aim to prolong survival and maintain quality of life for men facing urogenital malignancies.

A broad oncology program investigates solid tumors across multiple sites, focusing on improving disease‑free and overall survival. Studies include adding everolimus to endocrine therapy for high‑risk breast cancer, evaluating novel antibody‑drug conjugates for HER2‑low metastatic disease, and testing neoadjuvant BRAF‑targeted regimens in colorectal cancer.

• Everolimus augmentation of hormone therapy in ER+/HER2‑ breast cancer
• Trastuzumab‑deruxtecan for HER2‑low metastatic breast cancer
• Neoadjuvant encorafenib plus cetuximab in BRAF‑mutated colorectal cancer
• Adjuvant treatment strategies for stage III colon cancer in older adults
• Organ preservation approaches using contact X‑ray brachytherapy for rectal cancer

Through these diverse trials, Clinique De La Sauvegarde strives to set new standards of care for patients with various neoplastic conditions.